Since the discovery of actionable mutations, including the rearrangements of anaplastic lymphoma kinase (ALK) and echinoderm microtubule–associated protein–like 4 (EML4) genes, targeted therapies have dramatically improved survival outcomes in patients with NSCLC. Here, ALK is linked to non-small cell lung carcinoma.